On November 16, 2024, the China Meheco Group Pharmaceutical Industry Development Conference and the Shanghai International Biomedical Industry Week were held in Shanghai. The data released at the conference showed that since the 14th Five-Year Plan, the quantity and quality of domestically produced innovative drugs in China have both risen. A total of 113 domestically produced innovative drugs have been approved for market launch, which is 2.8 times the number approved during the 13th Five-Year Plan period, with a market size of 100 billion yuan. China's high-end medical instruments are accelerating innovation breakthroughs, with 165 innovative medical instruments developed by Chinese companies approved for market launch. These products integrate cutting-edge technologies such as deep learning, magnetic levitation, and additive manufacturing. During the 14th Five-Year Plan period, China had a total of 130,000 large-scale pharmaceutical and medical instrument enterprises capable of producing over 200,000 varieties of pharmaceuticals and medical instruments. The conference highlighted the significant progress in industrial upgrading and the key areas for future industrial technological development in the pharmaceutical industry during the 14th Five-Year Plan period. It also held the signing ceremony for the Joint Training Base of National Outstanding Engineers (Digital Technology Field) in the pharmaceutical industry—Digital Engineers for the Pharmaceutical Industry. Representatives of Chinese and foreign pharmaceutical companies jointly launched the Global Cooperation and Development Initiative for the pharmaceutical industry on site. (Yicai)